S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up

iTeos Therapeutics (ITOS) Insider Trading & Ownership

$9.22
-0.53 (-5.44%)
(As of 11/27/2023 ET)
Compare
Today's Range
$9.06
▼
$9.76
50-Day Range
$8.58
▼
$12.51
52-Week Range
$8.20
▼
$23.00
Volume
267,116 shs
Average Volume
296,687 shs
Market Capitalization
$329.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

iTeos Therapeutics (NASDAQ:ITOS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
10.20%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$41,850.00
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$5.69 M
Get ITOS Insider Trade Alerts

Want to know when executives and insiders are buying or selling iTeos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ITOS Insider Buying and Selling by Quarter


iTeos Therapeutics Insider and Congressional Trades History

Export to Excel
Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2023Matthew GallCFOBuy5,000$8.37$41,850.00  
8/23/2023Boxer Capital, LlcInsiderSell350,000$16.26$5,691,000.00  
(Data available from 1/1/2013 forward)












ITOS Insider Trading Activity - Frequently Asked Questions

Who is on iTeos Therapeutics's Insider Roster?

The list of insiders at iTeos Therapeutics includes Aaron I Davis, Ansbert Gadicke, Bioventures 2014 L.P. Mpm, Bioventures 2018 L.P. Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Matthew Gall, Michel Detheux, and Yvonne Mcgrath. Learn more on insiders at ITOS.

What percentage of iTeos Therapeutics stock is owned by insiders?

10.20% of iTeos Therapeutics stock is owned by insiders. Learn more on ITOS's insider holdings.

Which iTeos Therapeutics insiders have been buying company stock?

The following insiders have purchased ITOS shares in the last 24 months: Aaron I Davis ($968,400.00), and Matthew Gall ($41,850.00).

How much insider buying is happening at iTeos Therapeutics?

Insiders have purchased a total of 35,000 ITOS shares in the last 24 months for a total of $1,010,250.00 bought.

Which iTeos Therapeutics insiders have been selling company stock?

The following insiders have sold ITOS shares in the last 24 months: Aaron I Davis ($18,292,500.00), Bioventures 2018 L.P. Mpm ($7,300,828.04), Boxer Capital, Llc ($25,966,835.25), David Hallal ($2,201,346.21), Detlev Biniszkiewicz ($181,650.00), Joanne Jenkins Lager ($1,160,180.00), Matthew Gall ($232,250.00), Michel Detheux ($3,139,944.52), and Yvonne Mcgrath ($367,600.00).

How much insider selling is happening at iTeos Therapeutics?

Insiders have sold a total of 2,101,774 iTeos Therapeutics shares in the last 24 months for a total of $58,843,134.02 sold.


More Insider Trading Tools from MarketBeat

Related Companies:
Insider Tracking Tools:
Insider Trading By Country:
Latest Articles:
This page (NASDAQ:ITOS) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -